The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.
Patients must to be 12 years old (inclusive) at the time of signing the informed consent.
Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician.
Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent.
Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures.
Patients currently participating in any other clinical trial.
Known history of allergy or reaction to any component of the study treatment formulation.
Malignancy of any kind.
Patients with prior or ongoing treatment with benralizumab.
severe eosinophilic asthma
Cohort
Prospective
benralizumab
Other interventionnon-interventional
asthma control questionnaire
To describe the change in asthma control questionnaire at early time point after initiation of benralizumab
asthma control questionnaire
* Changes from baseline in ACQ-6 at week 1, 2, 4, 16, 24, 40 and 56 after initiation of benralizumab. * The percentage of patients well controlled (defined as ACQ-6 score ≤0.75), partially controlled (defined as ACQ-6 score \>0.75 and \< 1.5) and uncontrolled (defined as ACQ-6 score ≥1.5) at week 1, 2, 4, 8, 16, 24, 40 and 56. * The percentage of patients who had clinically meaningful change of ACQ-6 (defined as at least (≥) 0.5-unit improvement in ACQ-6 score) at the end of treatment at week 1, 2, 4, 8, 16, 24, 40 and 56.
changes in lung function
Changes from baseline in pre-BD FEV1 at week 8, 16 and 56 after initiation of benralizumab.
Click on the lead sponsor to view all of their trials.
